Archives of Ophthalmology (ARCH OPHTHALMOL-CHIC)
Continuing the Publication Founded by Herman Knapp, MD, in 1869. The objective of the Archives of Ophthalmology is education: To inform its readers of progress, problems, and pertinent research in the practice of ophthalmology through the publication of original contributions and observations.
Current impact factor: 4.40
Impact Factor Rankings
|2015 Impact Factor||Available summer 2016|
|2014 Impact Factor||4.399|
|2013 Impact Factor||4.488|
|2012 Impact Factor||3.826|
|2011 Impact Factor||3.711|
|2010 Impact Factor||3.516|
|2009 Impact Factor||3.859|
|2008 Impact Factor||3.242|
|2007 Impact Factor||2.984|
|2006 Impact Factor||3.206|
|2005 Impact Factor||3.274|
|2004 Impact Factor||2.926|
|2003 Impact Factor||3.203|
|2002 Impact Factor||2.337|
|2001 Impact Factor||2.424|
|2000 Impact Factor||2.158|
|1999 Impact Factor||2.453|
|1998 Impact Factor||2.426|
|1997 Impact Factor||2.476|
|1996 Impact Factor||2.692|
|1995 Impact Factor||2.352|
|1994 Impact Factor||2.01|
|1993 Impact Factor||2.066|
|1992 Impact Factor||2.007|
Impact factor over time
|Website||Archives of Ophthalmology website|
|Other titles||Archives of ophthalmology (1960), Archives of ophthalmology|
|Material type||Periodical, Internet resource|
|Document type||Journal / Magazine / Newspaper, Internet Resource|
- Author cannot archive a pre-print version
- Author cannot archive a post-print version
- 12 months embargo
- Only if in receipt of funding from a not-for-profit organisation, articles can be deposited after 12 months embargo
- On non-commercial open access repository, such as PubMed Central
- Must link to publisher version
- Publisher's version/PDF may be used
Publications in this journal
- [Show abstract] [Hide abstract]
ABSTRACT: IMPORTANCE The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, vitamin E, beta carotene, and zinc with copper. The Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk for lung cancer from beta carotene in smokers and former smokers and because lutein and zeaxanthin are important components in the retina. OBJECTIVE To further examine the effect of lutein/zeaxanthin supplementation on progression to late AMD. DESIGN, SETTING, PARTICIPANTS The Age-Related Eye Disease Study 2 is a multicenter, double-masked randomized trial of 4203 participants, aged 50 to 85 years, at risk for developing late AMD; 66% of patients had bilateral large drusen and 34% had large drusen and late AMD in 1 eye. INTERVENTIONS In addition to taking the original or a variation of the AREDS supplement, participants were randomly assigned in a factorial design to 1 of the following 4 groups: placebo; lutein/zeaxanthin, 10 mg/2 mg; omega-3 long-chain polyunsaturated fatty 3 acids, 1.0 g; or the combination. MAIN OUTCOMES AND MEASURES Documented development of late AMD by central, masked grading of annual retinal photographs or by treatment history. RESULTS In exploratory analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of the development of late AMD was 0.90 (95% CI, 0.82-0.99; P = .04). Exploratory analyses of direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.82 (95% CI, 0.69-0.96; P = .02) for development of late AMD, 0.78 (95% CI, 0.64-0.94; P = .01) for development of neovascular AMD, and 0.94 (95% CI, 0.70-1.26; P = .67) for development of central geographic atrophy. In analyses restricted to eyes with bilateral large drusen at baseline, the direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.76 (95% CI, 0.61-0.96; P = .02) for progression to late AMD, 0.65 (95% CI, 0.49-0.85; P = .002) for neovascular AMD, and 0.98 (95% CI, 0.69-1.39; P = .91) for central geographic atrophy. CONCLUSION AND RELEVANCE The totality of evidence on beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta carotene in the AREDS-type supplements. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00345176.Archives of Ophthalmology 12/2013; 132(2). DOI:10.1001/jamaophthalmol.2013.7376
- Archives of Ophthalmology 12/2012; 130(12):1559-1559.
- [Show abstract] [Hide abstract]
ABSTRACT: Objective: To compare the cost-effectiveness of 2 approaches for treating unilateral nasolacrimal duct obstruction (NLDO). Methods: One hundred sixty-three infants aged 6 to less than 10 months with unilateral NLDO were randomly assigned to receive immediate office-based nasolacrimal duct probing (n = 82) or 6 months of observation/ nonsurgical management (n = 81) followed by probing in a facility for persistent symptoms. Main Outcome Measures: Treatment success was defined as the absence of clinical signs of NLDO (epiphora, increased tear lake, mucous discharge) on masked examination at age 18 months. Cost of treatment between randomization and age 18 months included costs for all surgical procedures and medications. Results: In the observation/deferred facility-probing group, NLDO resolved within 6 months without surgery in 44 of the 67 patients (66%; 95% CI, 54% to 76%) who completed the 6-month visit. Twenty-two (27%) of the 81 patients in the observation/deferred facility-probing group underwent surgery, 4 of whom were operated on within the initial 6 months. At age 18 months, 69 of 75 patients (92%) in the immediate office-probing group were treatment successes, compared with 58 of 71 observation/deferred facility-probing group patients (82%) (10% difference in success; 95% CI,-1% to 21%). The mean cost of treatment was $562 in the immediate office-probing group compared with $701 in the observation/ deferred facility-probing group (difference, -$139; 95% CI, -$377 to $94). The immediate office-probing group experienced 3.0 fewer months of symptoms (95% CI, -1.8 to -4.0). Conclusions: The immediate office-probing approach is likely more cost-effective than observation followed by deferred facility probing if needed. Adoption of the immediate office-probing approach would result in probing in approximately two-thirds of infants whose obstruction would have resolved within 6 months of nonsurgical management, but would largely avoid the need for probing under general anesthesia. Application to Clinical Practice: Although unilateral NLDO often resolves without surgery, immediate office probing is an effective and potentially cost-saving treatment option. Trial Registration: clinicaltrials.gov Identifier: NCT00780741 Arch Ophthalmol. 2012;130(12):1525-1533Archives of Ophthalmology 12/2012; 130(12):1525-1533. DOI:10.1001/archophthalmol.2012.2853
- Archives of Ophthalmology 08/2012; 130(8):1059-1059.
- Archives of Ophthalmology 07/2012; 130(7):856-856.
- Archives of Ophthalmology 06/2012; 130(6):810.
- Archives of Ophthalmology 06/2012; 130(6):742-742.
- [Show abstract] [Hide abstract]
ABSTRACT: Objective: To determine how often nasolacrimal duct obstruction (NLDO) resolves with 6 months of nonsurgical management in infants aged 6 to less than 10 months. Methods: As part of a randomized trial evaluating the cost-effectiveness of immediate office probing vs observation with deferred probing for unresolved cases, 107 infants aged 6 to less than 10 months who had NLDO and no history of nasolacrimal duct surgery were prescribed 6 months of nasolacrimal duct massage and topical antibiotics as needed. Resolution of the NLDO was assessed 6 months after study entry and was defined as the absence of all clinical signs of NLDO (epiphora, increased tear lake, or mucous discharge) and not having undergone NLDO surgery. Exploratory analyses assessed whether baseline characteristics, including age, sex, laterality, and prior treatment, were associated with the probability of NLDO resolving without surgery. Results: At the 6-month examination, which was completed for 117 of the 133 eyes (88%), the NLDO had resolved without surgery in 77 eyes (66% [95% CI, 56%-74%]). None of the baseline characteristics we evaluated were found to be associated with resolution. Conclusions: In infants 6 to less than 10 months of age, more than half of eyes with NLDO will resolve within 6 months with nonsurgical management. Knowledge of the rate of NLDO resolution in infancy without surgery will help clinicians and parents effectively discuss treatment options.Archives of Ophthalmology 06/2012; 130(6):730-734.
- Archives of Ophthalmology 05/2012; 130(5):654-654.
Article: Interview With Stephen J. Ryan, MDArchives of Ophthalmology 05/2012; 130(5):650-651.
- Archives of Ophthalmology 04/2012; 130(4):433. DOI:10.1001/archophthalmol.2011.1626
Article: Multiple Macular HolesArchives of Ophthalmology 04/2012; 130(4):455. DOI:10.1001/archopthalmol.2011.1394
- Archives of Ophthalmology 03/2012; 130(3):364. DOI:10.1001/archopthalmol.2011.1937
- Archives of Ophthalmology 03/2012; 130(3):379-379.
- Archives of Ophthalmology 03/2012; 130(3):328-328.
- Archives of Ophthalmology 03/2012; 130(3):382-382.
- Archives of Ophthalmology 02/2012; 130(2):170. DOI:10.1001/archopthalmol.2011.1243
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.